You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 27, 2021

Indonesia Updates Its Drug Advertising Guidelines

Subscribe to Updates

In February 2021, Indonesia’s National Agency for Drug and Food Control (Badan Pengawas Obat dan Makanan, or BPOM) issued updated guidelines for the advertising of pharmaceutical products. Regulation 2/2021 concerning the Supervision of Drug Advertising Guidelines, which came into effect on February 3, 2021, improves the process for the submission and consideration of advertisement approval requests, expands the categories of media and drugs that are not allowed to be advertised, defines supervisions and sanctions, and better clarifies drug labeling and advertisement to prevent pharmaceutical companies from mislabeling drugs and clamp down on drug advertisement violations online.

At the same time, BPOM revoked Regulation 8/2017 concerning the Supervision of Drug Advertising Guidelines. This old version from 2017 was updated by the new regulation in several important ways.

Online Application System for Advertisement Approval

BPOM now operates an online advertisement approval application system known as SIAPIK (from its full name, Sistem Aplikasi Persetujuan Iklan). The use of this online system, which is available at https://siapik.pom.go.id, is a step forward from the previous practice in which advertisement applications had to be filed in person.

BPOM Regulation 2/2021 regulates the submission of advertisement approval applications via the SIAPIK website. These applications must include a marketing authorization approval letter, the approved label or label design, and the advertising design. Advertising documents in English are accepted, but documentation in any other foreign (or local) language must be translated into Bahasa Indonesia. Applications should also include supporting documents containing certain information that is not related to the use of drugs, if required by the officer for verification.

After the documents are submitted, BPOM evaluates the advertisement approval using the appropriate process for the category into which the advertisement falls. Those in the “minor” category include advertisements with new concepts that do not have the potential to cause misinterpretation, as well as variations (such as small alterations to the information, and other insignificant changes) on advertisements that have already been approved. Those in the “major” category include advertisements with new concepts that have the potential to lead to wrong interpretations, and variations of advertisements (or meaningful changes) that have already been approved and have undergone no other notable change (e.g., in advertisement media, in reduction of claims, or through shortening of duration that could alter interpretations of the advertisement).

The evaluation period is 10 working days for minor category advertisements and 25 working days for major category advertisements—both significantly shorter than the 60 days for evaluation (regardless of category) specified in the previous regulation.

Evaluation results are then issued electronically—approved if the application has met all the requirements, or rejected if the application has failed to do so. An approval of an advertisement is valid for as long as the marketing authorization of the drug lasts and as long as the advertisement still meets the criteria and requirements.

The SIAPIK system also provides a “notification service,” which applicants can use to apply for renewal of unchanged advertisements or approval for variations to already-approved advertisements, if the changes are to:

  • design or layout, without changing the claims or information contained in the advertisement;
  • the cast appearing in the advertisement;
  • publication means, without any change in advertisement media as defined in article 7(2), 7(3), and 7(4) (see discussion of media categories below); or
  • reduction of claims or shortening of duration that does not result in a change to the interpretation or meaning of the advertisement.

Applications using the notification service are processed automatically via the SIAPIK system, with independent evaluation by the applicant (that is, self-assessment without BPOM evaluation) within one working day.

Media Category for Drug Advertisements

BPOM Regulation 2/2021 also expands the definitions of advertising publication media in which drugs can be advertised to three broad categories:

  1. visual media
  2. audio media (which includes audio accompanied by a static image online), and
  3. audiovisual media (such as an online video).

This is a significant change from the previous regulation’s media categories of only printed, electronic, and outdoor media.

Advertisements in the form of interactive communication (e.g., telephone, social media, chat rooms, and instant messaging), whereby information is transmitted between the advertiser and the public, are permitted as long as they meet all regulatory requirements, contain complete and truthful information,  and are in compliance with the approved advertisement.

Unlike BPOM Regulation 8/2017, the new regulation requires advertisements using visual media to provide a contact for customer service.

Advertising Controls and Prohibitions for Specific Drugs

The list of specific drugs that require additional information in their advertisements remains the same, but in the new regulation this has been moved into the body (instead of an appendix). These drugs include the following:

  • Cough medicine or flu medicine
  • Asthma medication
  • Indigestion medicine
  • Anthelmintic
  • Topical drugs for fungal infections
  • Eye drops
  • Mouthwash
  • Sore throat medication
  • Bruise medicine
  • Anemia medicine
  • Laxatives
  • Motion sickness medication
  • Malaria drugs
  • Diarrhea medicine

Advertisements for prescription drugs, narcotics, and psychotropic drugs are exempted from having to include specific information if the advertisements are addressed to healthcare workers.

One change reflected in the new regulation is an expansion of the types of drugs prohibited from being advertised to the public. In Regulation 8/2017, “G-list drugs,” or prescription drugs, are prohibited from being advertised to the public. In Regulation 2/2021, this prohibition on public advertisements covers prescription drugs, narcotics, and psychotropic drugs.

Supervision of Advertisements

Officers continue to have the authority to monitor airing advertisements and re-evaluate approved advertisements. However, Regulation 2/2021 allows the public to participate in advertisement supervision as well by providing information or reports on suspected advertisement violations. The report should be submitted to the head of BPOM electronically to the official BPOM email address for public complaints ([email protected]) or by telephone (1500533). The information can also be submitted in writing to the director of safety, quality and import export control of drugs, narcotics, psychotropics, precursors, and addictive substances.

Sanctions

BPOM Regulation 2/2021 stipulates a number of administrative sanctions, depending on the severity of a violation. At the lower end of the scale are warnings (from a written notice to a more serious warning), followed by orders to correct, stop, or withdraw published advertisements. Offenders may also be punished by a temporary suspension of advertising activities, or a freezing or revocation of a marketing authorization permit.

Conclusion

While Regulation 2/2021 does not represent a fundamental change to drug advertising in Indonesia, there are several significant updates that pharmaceutical companies need to be aware of before planning an advertising campaign in Indonesia or submitting a drug advertisement application. The regulations for using the SIAPIK online system, amended categories and prohibitions, and public involvement in supervising advertisements are important updates that both have the potential to affect companies’ advertising plans and help maintain the relevance and effectiveness of Indonesia’s drug advertising regulatory environment.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

June 24, 2026
Patent enablement requirements are provided under Article 102 of Vietnam’s Law on Intellectual Property (IP Law). In particular, a patent specification must “fully and clearly disclose the nature of the invention to such an extent that, based on the specification, a person having ordinary skill in the relevant art can implement the invention.” In pharmaceutical and biotechnology patents, this requirement is more complicated and subject to more rigorous assessment. The Patent Examination Guidelines (Guidelines) of the Intellectual Property Office of Vietnam (IP Office) were amended in March 2026 to introduce Annexes III and IV for the pharmaceutical and biotechnology sectors, in which Annex III provides detailed guidelines on the assessment of specification requirements. These amendments were made under a project for strengthening capacity in industrial property examination between the Japan International Cooperation Agency (JICA) and the IP Office. Annex III provides detailed instructions on how examiners assess enablement in a pharmaceutical or biotechnology application, and offers examples of acceptable and unacceptable descriptions with regard to the enablement aspect. Enablement Requirements in Pharma and Biotech Patents Article 12.7 of Circular 10/2026/TT-BKHCN (Circular 10) adds to the requirements of Article 102 of the IP Law that the description must demonstrate the novelty, inventive step, and industrial applicability of the technical solution. For pharmaceutical composition subject matters, Article 12.9 of Circular 10 sets out that the description must present the results of clinical trials and/or the pharmacological effects of the claimed pharmaceutical composition, and must include at least the following information: Substance/mixture used. Testing method (system) employed. Information on the test results. Correlation between the pharmacological effects obtained from the tests and the application of the pharmaceutical product in the prevention, diagnosis, and treatment of diseases. The Guidelines note that pharmacological study results should be presented in a quantified manner, and pharmacological
Read More
June 19, 2026
For the first time, Thailand’s Food and Drug Administration (FDA) has published a consolidated list identifying all substances that have successfully passed its novel food safety evaluation process. The list is a step forward in regulatory transparency, but it also highlights a feature of the Thai regime that food companies often overlook: each approval is tied exclusively to the company that applied for it. A substance’s appearance on the list does not give other companies the green light to use it. This article examines the structure of Thailand’s novel food approval framework, the implications of applicant exclusivity, and the strategic choices it requires of food companies looking to bring novel ingredients to the Thai market. Thai FDA Food Safety Evaluation Framework Notification No. 376 of the Ministry of Public Health requires novel food substances to undergo a food safety assessment, with an exemption only for novel foods manufactured exclusively for export. The framework also encompasses “foods that do not qualify as novel foods” but which present characteristics warranting a safety evaluation, such as differing quality standards, increased serving sizes, or applications in specific food categories, where such changes affect consumption levels, nutritional value, or consumer safety. The recently published list of foods that passed the safety evaluation by the Thai FDA is structured by substance category and identifies the approved company (domestic manufacturer or importer), country of origin, substance name and trade name, approved purpose of use, and date of the Thai FDA’s approval notification certificate. A notable feature of Thailand’s novel food regime is that the approval result is tied exclusively to the company that submitted the application. Publication of the consolidated list does not constitute a general authorization to use the approved substances. The Thai FDA’s approval certificate specifies the approved conditions of use and the requirements
Read More
June 17, 2026
Thailand’s new labeling requirements for medical devices, which include for the first time a unique device identification (UDI) requirement for software as a medical device (SaMD), take effect on June 20, 2026. The Notification of the Ministry of Public Health regarding Criteria, Methods, and Conditions on Labeling and Instructions for Use for Medical Devices 2025, which replaces a similar notification from 2020, was published in the Government Gazette on December 22, 2025. To ensure clarity, modernity, and patient safety, the regulation requires domestic manufacturers and importers to provide labels and instructions for use (IFU) that are clearly legible, complete, and free of false or misleading claims. It also permits IFU to be provided in electronic format, such as via QR codes, websites, or other digital channels—directly relevant to SaMD, where physical labels are impractical and electronic presentation is the natural medium. The notification distinguishes two categories for labeling language. Home-use medical devices (for lay users outside healthcare facilities) must have labels and IFU in Thai. Professional-use medical devices may display labels and documentation in either Thai or English. This distinction is significant for SaMD developers: software intended for clinical professionals may use English-language interfaces and IFU, while consumer-facing health applications must provide Thai-language content. Labeling and UDI Requirements Labels and IFU must include, at a minimum: Product name and intended purpose Quantity or volume Name and address of domestic manufacturer or importer Thai FDA approval number Lot, version, or serial number Manufacturing date and expiry date For SaMD, the version number requirement is particularly relevant. The regulation also mandates display of a UDI code for SaMD in risk category 2 (moderate-risk), category 3 (moderate- to high-risk), and category 4 (high-risk), according to Thailand’s medical device risk classification system (which complies with the ASEAN Medical Device Directive and the EU
Read More
June 5, 2026
On May 25, 2026, Vietnam’s Ministry of Health issued Circular No. 16/2026/TT-BYT governing free-of-charge medicine support programs for medical establishments (Circular 16). Circular 16 will take effect on July 10, 2026, replacing Circular No. 31/2018/TT-BYT, which currently regulates the same subject matter. Circular 16 introduces several significant changes compared to the existing legal framework. Removal of Prior Approval Requirement Under the current regulations, free-of-charge medicine support programs are divided into two categories: (1) entirely free-of-charge provision of medicines for all types of drugs and (2) partially free-of-charge provision applicable only to brand-name drugs under patent protection or drugs whose generic products with identical active ingredients and dosage forms are available in Vietnam. Under the current regulations, partially free-of-charge programs are subject to mandatory registration with the competent authority, while entirely free-of-charge programs could be implemented without prior approval. A key reform under Circular 16 is that it stipulates only entirely free-of-charge medicine support programs applicable to all types of medicines, thereby eliminating the partially free-of-charge category. In addition, free-of-charge medicine support programs may be carried out solely based on a written agreement between the pharmaceutical company and the medical establishment, without any requirement for prior approval from competent authorities prior to implementation. Written Agreement Requirements Circular 16 requires the pharmaceutical company and medical establishment to enter into a written agreement in accordance with a prescribed template. This agreement must include the following compulsory information: Information on the supported medicines Form of support (entirely free-of-charge provision to patients) Quantity of medicines provided Target patient groups and applicable indications Duration of the program Rights and obligations of each party Transitional provisions on the protection of patients’ rights upon completion of the program The agreement may contain other contents as agreed by the parties, provided that these do not contradict applicable laws.
Read More